Paratek Pharmaceuticals competitors

Mr. Wise became Chief Executive Officer, and joined the Company’s Board of Directors, in January 2018. Mr. Wise joined Achaogen as Chief Operating Officer in 2015 and, in February 2017 he was appointed President and Chief Operating Officer.Prior to Achaogen, Mr. Wise spent 13 years at Genentech, where he established and led the Cross BioOncology franchise as Vice President, Cross BioOncology. In this role, Mr. Wise spearheaded cross-portfolio initiatives designed to drive the $10B US BioOncology business and the company’s long-term oncology strategy. During his time at Genentech, Mr. Wise also held several other leadership positions of increasing responsibility, including Senior Director, Franchise Head and Life Cycle Leader of the Lytics franchise, with overall commercial responsibility for Genentech’s hospital-based Lytics business. He previously served as a Sales Director in BioOncology, Marketing Director in Cystic Fibrosis and Immunology, and Interactive Marketing Director where he built Genentech’s digital marketing capabilities. Prior to joining Genentech in 2002, Mr. Wise worked in consumer marketing, e-commerce and online marketing outside of the healthcare industry in leadership positions at Gap, Inc. and Webvan.

Clive Richardson is a Board Member at Akari Therapeutics PLC. He has worked as Head:Operations at Volution Immuno Pharmaceuticals SA, Board Member at CLINISYS SOLUTIONS LIMITED, and Interim CEO/COO at Akari Therapeutics PLC. Clive works or has worked as Head:Equities Research at Investec. He attended Trinity College Oxford.

Mr Butler joined Akebia as President and CEO in September, 2013. He has more than 25 years of experience leading the development, launch and commercialization of innovative therapies. He served as CEO of Inspiration Biopharmaceuticals, a company focused on developing products for patients with hemophilia, from 2011 until 2013. He led the sale of the company’s assets, including the company’s lead asset to Baxter Corporation, the world leader in hemophilia. The value of the transactions should total over $1 billion to Inspiration’s shareholders. From 1997 to 2011, Mr Butler held various positions at Genzyme Corporation, one of the world’s largest biotechnology companies. While at Genzyme, he most recently served as President of the company’s rare genetic diseases business, which has developed and commercialized first-to-market, transformative therapies for small patient populations. Mr Butler also led the company’s renal, endocrinology, and cardiovascular businesses, growing the division to $1 billion in revenue. Earlier in his career, he held sales and marketing positions at Amgen and Hoffmann-La Roche. He has spent over twenty years working to improve the lives of patients with kidney disease. He served in a number of commercial roles while at Amgen for Epogen® and he led the renal business at Genzyme which brought Renagel®, Renvela®, and Hectorol® to these patients. He currently serves as the chairman of the American Kidney Fund board of trustees. The AKF is the leading patient focused charitable organization in kidney disease, providing assistance to one in 5 patients on kidney dialysis in the US. Mr Butler received his BA degree in Chemistry from Manhattan College and his MBA degree from Baruch College.

President, Chief Executive Officer and Director of SCYNEXIS Inc. (Nasdaq: SCYX) and Director of various public companies and non-profit organizationsCompleted several successful rounds of financing and company restructuringExperience as a Director in Boards of public companies (Audit Committee, Compensation Committee and Governance & Nominating Committee) Managed groups up to 1,600 employees in global organizations and R&D budgets up to $950MM/yearOver 35 products approved through various regulatory paths [505(b)1, 505(b)2, 510(k) devices and ANDA] in the US and globally in Europe and South America:Anti-Infectives: Cedax (ceftibuten, Global), Isepacin (isepamicina - Europe), Cleeravue-M (minocycline for skin infections - US), Teflaro (ceftaroline - US), Colobreathe (Inhaled Colistin for cystic fibrosis - Europe), Avycaz (Ceftazidime/Avibactam)Oncology: Intro-A (Interferon-α in Non-Hodgkin lymphoma - US), Fareston (toremifene for breast cancer -US), Temodar (Temozolomide for brain tumors- Global) Central Nervous System: Subutex (buprenorphine for opioid addictions, Global), Savella (milnacipran for fibromyalgia - US), Lexapro pediatric (escitalopram - US), Namenda XR (memantine for Alzheimer disease, US), Fetzima (levomilnacipran for Major Depression Disorder - Global) Cardiovascular: Bystolic (nebivolol for hypertension - US)Gastroenterology: Linzess (linaclotide for IBSc and CIC - US)Respiratory Medicine: Daliresp (roflumilast for COPD - US), Tudorza (Aclidinium for COPD - US)Dermatology: Lotrisone Lotion (US for eczema), Mometasone Pediatric (US), MimyX (US), Duac (Global), Ciclopirox Shampoo (Global), Ciclopirox solution (Global), Rosac Wash (US), Brevoxyl Pads (US), Levulan (Global)Generics (US): Griseofulvin Suspension, Sodium Sulfacetamide Wash, Urea CreamOTC/Cosmeceuticals: Physiogel sunscreen (International), PanOxyl 10%, Foaming Acne Wash, Clariderm (International), Mimyx (US), SunMAX line (International), LactiCare HC (International)

John Ratliff served as Chief Executive Officer of Covance Drug Development, the world’s most comprehensive drug development company. He is a highly respected biopharmaceutical leader, with extensive experience in increasingly influential roles in the industry. In 2018, Ratliff was appointed Chairman for the Association of Clinical Research Organizations. Previously John was president and CEO of HUYA Bioscience International. His healthcare industry experience also includes almost 10 years at Quintiles, the world’s largest provider of product development and integrated healthcare services, where he served as Chief Financial Officer before becoming President and Chief Operating Officer. He was a member of the Quintiles board of directors. Prior roles throughout his career included CFO at Acterna, a provider of communications test solutions for telecommunications and cable network operators, and positions of increasing responsibility during his 19-year tenure at IBM.

Daryl Mims is a Global Business Partner, CEO/CIO and many VPs at OPTIMER PHARMACEUTICALS INC and is based in Sewaren, New Jersey. He has experience at National Basketball Association (NBA) and has worked as Helpdesk Analyst at Medco Health Solutions, Inc. and Desktop Support / Consultant at Verizon Corporate HQ. Daryl attended Bayonne High School between 1991 and 1995.